 Sage Therapeutics Inc NASDAQ: SAGE and Biogen Inc NASDAQ: BIIB have announced 12-month data for the cohort of patients n199 who received zuranolone 50 mg once for 14-days as their initial dose in the ongoing Phase 3 open-label SHORELINE Study. Related: Sage Therapeutics - Biogens Zuranolone Tops Placebo In Reducing Depressive Symptoms. 